What is ACAD's health score?

ACADIA PHARMACEUTICALS INC (ACAD) has a TradeApes health score of 45 out of 100, rated Mixed. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is ACAD's estimated fair value?

Based on our 5-year discounted cash flow model, ACADIA PHARMACEUTICALS INC's estimated fair value is $20.8 per share, representing a -4.3% downside from the current price. This is a model estimate, not a price target or investment recommendation.

Is ACAD undervalued or overvalued?

Our model currently rates ACAD as Fair Value. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for ACAD... Refresh in a moment for the full analysis.

ACADIA PHARMACEUTICALS INC (ACAD)

Healthcare Fair Value low mixed

$21.72

Updated: 2026-06-05

TradeApes Score

Financial Strength

40 Weak

Operating Trend

55 Mixed

Relative Value

35 Weak

Capital Allocation

30 Weak

Risk

80 Strong

Est. Fair Value $20.8

DCF Upside -4.3%

Sector Rank #2194 of 6952

Key Findings

+ Strong revenue growth — sales up more than 20% year over year

Unlock Full Report →

− Historically expensive — EV/EBITDA in top 20% of its 5-year range

Unlock Full Report →

2 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.